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Abstract 
Purpose 
A clinical pathway for anxiety and depression in adult cancer patients was developed 
to guide best practice in Australia. 
Methods 
The pathway was based on a rapid review of existing guidelines, systematic reviews 
and meta-analyses, stakeholder interviews, a Delphi process with 87 multi-
disciplinary stakeholders and input from a multidisciplinary advisory panel.  
Results 
The pathway recommends formalised routine screening for anxiety and depression in 
patients with cancer at key points in the patient’s journey. The Edmonton Symptom 
Assessment System (ESAS) or Distress Thermometer (DT) with problem checklist 
are recommended as brief screening tools, combined with a more detailed tool, such 
as the Hospital Anxiety and Depression Scale (HADS), to identify possible cases. A 
structured clinical interview will be required to confirm diagnosis.  
When anxiety or depression is identified it is recommended one person in a treating 
team takes responsibility for co-ordinating appropriate assessment, referral and 
follow-up (not necessarily carrying these out themselves). 
A stepped care model of intervention is proposed, beginning with the least intensive 
available that is still likely to provide significant health gain. The exact intervention, 
treatment length and follow up timelines as well as professionals involved, are 
provided as a guide only. Each service should identify their own referral network 
based on local resources and current service structure, as well as patient preference. 
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Discussion 
This clinical pathway will assist cancer services to design their own systems to detect 
and manage anxiety and depression in their patients, to improve the quality of care.   
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Introduction 
Anxiety and depression impact on family and social functioning, work performance, 
suicidal ideation, and survival [1]. The existential turmoil generated by a cancer 
diagnosis, and its impact on patients’ psychological, social and physical functioning, 
render these patients vulnerable to anxiety and depression. High levels of these 
morbidities have been found in cancer patients across demographic backgrounds and 
cancer types and stages [2-4]. For example, a large (n=10,153) Canadian study found 
that just under a quarter of all cancer patients had clinical or subclinical levels of 
anxiety while clinical or subclinical levels of depression were present in up to 16.5% 
of the sample[5]. Similarly, in a large German study (n=4020) using stratified, 
purposive sampling, the 4-week prevalence rates for any mental disorder, anxiety, and 
mood disorder were 32%, 12% and 7% respectively [4]. Even higher rates were 
reported in a meta-analysis of studies with Chinese adults with cancer [6], while 
another recent meta-analysis reported some mood disorder in 30-40% of patients [7]. 
Rates can also be much higher in particular subgroups. For instance, the Canadian 
study found that more than half of patients who were female and/or aged below 50 
presented with clinical or subclinical anxiety[5].  
 
Despite high acceptance that psychosocial care is integral to quality cancer care, 
anxiety and depression are often undetected and under-estimated in busy cancer 
services [8], and high unmet need for psychosocial care is persistent in cancer patients 
[9]. This is despite the large evidence-base that interventions for anxiety and 
depression in patients with cancer are effective in the short and long-term [10-14]. 
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Because anxiety and depression are often under-detected, routine screening of all 
cancer patients for psychological distress using validated, reliable, objective 
measures, is internationally endorsed [15]. The International Psycho-Oncology 
Society (IPOS) and 68 affiliated organisations have set a standard of care involving 
monitoring distress as the “6th vital sign”.  
 
Screening has been shown to be acceptable and feasible [16]. However, results of 
trials evaluating the efficacy of distress screening have been mixed. A recent 
systematic review [16] identified 14 relevant randomized controlled trials (RCTs) and 
a further 10 non-randomized studies. Only six of the 14 RCTs reported impacts on 
patient well-being, sometimes only for those initially depressed at baseline. An 
additional three showed improved secondary outcomes such as communication 
between clinicians and patients. Five RCTs failed to show any benefits. The majority 
of these trials have focused on screening in isolation, some adding routine feedback to 
staff. Comparing successful with unsuccessful trials, it appears that strategies that 
minimize staff burden and ensure effective follow-up are critical.  
 
A number of guidelines exist internationally for the assessment and management of 
anxiety and depression in cancer patients [17-24]. However, most have limited 
guidance on specific timelines, roles and potential content of interventions, which are 
the hallmarks of effective clinical pathways.  
 
Clinical pathways provide evidence-based recommendations to guide best practice 
and consistent care for specific patient concerns in homogeneous patient groups. 
Research has shown that the implementation of clinical pathways significantly 
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increases detection of psychological morbidity and rates of referral for treatment, for 
example in heart disease [25].  The provision of clear clinical pathways in the cancer 
setting, in combination with staff training and effective intervention, should improve 
patient outcomes [7, 25]. The need for such a pathway is underlined by the recent 
American College of Surgeons patient-centred accreditation standard requiring 
programs to implement psychosocial distress screening and referral for psychosocial 
care [26, 27].  
 
Our group aimed to develop clinically relevant, evidence-based, and widely endorsed 
Australian clinical practice pathways for the screening and management of anxiety 
and depression in the cancer context.  
 
Methods 
This clinical pathway was developed based on:  
1) A rapid review of existing guidelines, systematic reviews and meta-analyses 
relevant to the screening, assessment and management of anxiety and depression in 
cancer patients and the general public [10-14, 16-24, 26-33]. We searched the 
Cochrane, Google, PubMed, Medline, Psychlit and Cinahl databases; 
2) Structured interviews with 12 key multi-disciplinary staff from different 
institutions [34]; 
3) An online Delphi process incorporating two rounds of feedback from 87 
stakeholders who are members of the Psycho-Oncology Co-operative Research 
Group (PoCoG), a national multidisciplinary trials group with over 1000 members 
and almost complete coverage of Australian clinicians and researchers interested in 
the psychosocial care of cancer patients [34]. Delphi participants were purposively 
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selected to ensure representation from all clinical stakeholder groups (psychiatry 
(n=4), psychology (n=16), social work (n=14), other allied health (n=10), palliative 
care (n=4), oncology (n=15), surgery (n=8), nursing (n=18) and general practice 
(n=1); and  
4) Input from a multidisciplinary advisory panel (10 experts from 7 different 
institutions, selected to ensure representation of all relevant disciplines, with > 10 
years experience relevant to the treatment of anxiety and depression in cancer 
patients).  
 
More details about these methods and their results are provided in Shaw et al [34]. 
Where possible existing high quality guidelines were utilized. Where key issues were 
not present in any guidelines they were addressed using the best available evidence 
supported by expert review.  
 
Results 
The section below presents a preamble to the pathway, with core principles and issues 
discussed.  
 
The recommendations made in the clinical pathways are intended as a guide only, and 
individual centres will need to adapt them to suit their own context and resources. 
Factors that need to be considered when tailoring the pathways include patient 
demographics, stage of illness and cancer type.   
 
PROFESSIONAL ROLES 
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Possible professional roles are outlined in Table 1. The appropriateness of referral and 
treatment will depend very much on what is elicited in the initial assessment, so doing 
this well is crucial. Health Professionals carrying out screening and/or follow-up 
assessment need to have the skills and confidence to comfortably discuss anxiety and 
depression with patients, and to facilitate referral. They also need to be able to 
respond with empathy to immediate feelings and concerns. For many patients it could 
be the first time they have spoken about anxiety and/or depression, and so screening 
and assessment needs to be conducted in a thoughtful and sensitive way. Individual 
skills and training within each team will determine who is best placed to undertake 
specific roles. No professional should take on any role for which they have not 
received training or which they do not feel competent to undertake. 
 
Note: the clinical pathway recommends a high level of involvement for general 
practitioners (family medicine doctors). While such a high level of involvement is 
typically the case for general practitioners (GPs) based in rural and remote areas, this 
is out of necessity, and urban GPs often have limited involvement in care while 
patients are undergoing active cancer treatment [35].  
 
SCREENING AND ASSESSMENT 
SCREENING 
While staff should always be alert to signs of anxiety or depression, this pathway 
recommends that formalised routine screening for anxiety and depression in patients 
with cancer be carried out using validated measures at key points in the patient’s 
journey. There is no established gold standard tool for this purpose. A number of 
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screening tools are available. No screening tool is foolproof; all should be 
supplemented by clinical interview. Several studies, including a recent meta-analysis 
by Mitchell et al [36], suggest that a two-step approach is best, where a very short 
screening tool, followed by a more detailed screening tool, are used to identify 
possible cases, and a clinical interview used to confirm diagnosis. We recommend 
using a validated screening measure that is fit for purpose (for comprehensive reviews 
of screening for distress see Carlson et al [37], for depression see Wakefield et al 
[38]) and for anxiety see Vodermaier et al [39]. 
 
There is merit in consistency of tools used for screening across centres, at least within 
one country, to allow bench-marking. Following an extensive review of the literature 
and current approaches to screening, the multidisciplinary panel, supported by Delphi 
participants, recommend either the Edmonton Symptom Assessment System (ESAS) 
[40], or Distress Thermometer (DT) with problem checklist [18], for use as the initial 
very brief screening tool. If possible anxiety and/or depression is identified by the 
very brief screening tool, it is recommended that patients complete a more detailed 
screening tool, such as the Hospital Anxiety and Depression Scale (HADS) [41]. 
Again, a variety of tools are available for this purpose (for a review, see Luckett et al 
[42]). On the basis of the literature, the multidisciplinary panel, supported by Delphi 
participants, recommended the HADS. If either or both the very brief and more 
detailed screening tools are used, they must be scored and discussed with each patient. 
A short description of the recommended tools follows, but institutions may choose 
different measures.  
The Edmonton Symptom Assessment System (ESAS):[ESAS; 40] consists of nine 
visual analogue items (0-10), including one for anxiety (ESAS-A) and one for 
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depression (ESAS-D). Recommended cut-offs for the ESAS-A of ≥3 and ESAS-D of 
≥2 ensure no possible case of anxiety or depression is missed [43]. One advantage of 
the ESAS is that it also assesses common symptoms (such as pain and fatigue) that 
may need to be addressed before or alongside anxiety and depression.  
 
The Distress Thermometer (DT) is a one-item visual analogue tool (0-10), which 
should be accompanied by a Problem List to identify areas of concern for patients 
[18]. According to a large (N=42), recent meta-analysis of data from 14,808 patients, 
optimal identification of anxiety and/or depression in a clinical oncology setting can 
be achieved by using a cut-off score of 4 or more on the DT [44]. An advantage of 
using the DT in conjunction with a problem list is that it identifies the specific areas 
of concern to target.  
 
The Hospital Anxiety and Depression Scale (HADS) [41] is a 14-item measure with 
two subscales. Seven items (rated 0-3) measure anxiety and 7 items (rated 0-3) 
measure depression. Items are summed within each subscale. A cut-off of 8 or more 
on either of the subscales is recommended to ensure no possible case of anxiety or 
depression is missed [45]. A score of 11 or more suggests possible moderate to severe 
anxiety or depression [45]. Clinical interview is recommended to confirm caseness of 
anxiety or depression.  
These tools can be completed by paper and pencil, online or electronically face-to-
face, using tablets. If online, patients can be cued by email to complete the first very 
short questionnaire; scores can be automatically summed; if above the cut-off, 
patients can be presented with the more detailed screening tool; and red flags can be 
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sent to responsible staff to initiate contact with patients who score above cut-off. It is 
recommended that one staff member is nominated to be responsible for ensuring that 
screening takes place at the appropriate times (see Table 1 for possible staff members 
to carry out this role). Note also, that re-screening is recommended within the 
pathway at clinically significant time points, such as recurrence.  
 
ASSESSMENT 
Determining severity of anxiety and depression: At any clinical encounter, staff 
should be alert to signs of anxiety and depression. If screening or staff observation 
identifies possible anxiety and/or depression, then a more comprehensive clinical 
assessment should be conducted. The assessment is typically a semi-structured 
interview that can be based on standardised diagnostic criteria (DSM-V or ICD-10) 
[46,47], and should aim to identify the nature of the primary problem and its possible 
causes; and the severity of relevant symptoms.  
 
Note that it is important to first identify any medical conditions that may be 
contributing to the presentation, such as treatment with steroids, unrelieved pain or 
withdrawal from drugs or alcohol. Delirium should also be considered and the cause 
(such as infection or electrolyte imbalance) identified and treated [17, 19]. Some 
alternative guidelines for such issues are provided in Figure 1 [22, 48-50]. Once these 
are resolved, re-screening for anxiety and depression should take place to determine if 
these are independently troublesome.  
Symptoms and severity: The signs, and categorisation of different levels of anxiety 
and depression according to severity, are shown in Tables 2 and 3. Symptoms of 
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anxiety in cancer patients are difficult to classify because they can be a normative or 
excessive reaction to cancer threats, a response to poor symptom control, an adverse 
effect of certain treatments or drug interactions, a clinical anxiety disorder, or a 
combination of these factors [51].  Level of anxiety or depression will ultimately be 
decided based on clinical judgment.  
 
It is recommended that one person takes responsibility for ensuring appropriate 
assessment, referral and follow-up are undertaken (but does not necessarily carry 
these out themselves). See Table 1 for appropriate personnel to carry out assessment 
and referral. Every health service with which a patient comes into contact (including 
general practice and surgery) will need to identify who are the most appropriately 
trained and supported staff members to: a) coordinate screening, assessment and 
referral, and b) carry out these processes. In some centres a different staff member 
may be identified within each tumour stream to coordinate and/or carry out this 
process.  
 
Suicide/ Self-Harm Risk Assessment: For patients with moderate or severe anxiety 
and/or depression, a formal risk assessment for suicide and self-harm should be 
conducted to assess previous history, strength of intent, means and capacity. Table 4 
provides risk factors and scoping questions that can be used for this purpose. 
 
STEPPED CARE 
Stepped care has proven to be an effective model of healthcare delivery, including the 
treatment of anxiety and depression [52, 53]. In stepped care, the first intervention 
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should be the least intensive of those currently available, which is still likely to be 
effective [50]. More intensive interventions are reserved for patients who do not 
benefit from simpler first line treatments [53]. Stepped care is self-correcting in that 
the outcomes of interventions are monitored systematically and care is stepped up if 
current interventions are not achieving significant health gain. For example, psycho-
education can be delivered via self-help materials with GP support accessed according 
to need. If this appears not to be meeting the patient’s needs and reducing morbidity, a 
referral to a psychologist should be considered.  
 
Patient preferences are critical in determining the most appropriate intervention, the 
intervention setting and the intervention provider. Given that the prevalence of 
anxiety and depression in the general community is quite high, patients may have an 
existing relationship with a mental health professional. Cancer diagnosis and 
treatment can often exacerbate pre-existing psychological issues. When referring for 
intervention, it is important to establish patient preferences for treatment through 
existing mental health care professionals or psycho-oncology services. 
 
The section below presents the Pathway itself. Figure 1 below provides an overview 
of the Clinical Pathway for Identifying and Managing Anxiety and Depression, 
utilising the stepped care approach.  
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Figure 1.  
Overview of the pathway and stepped care.  
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The five steps of the clinical pathway are summarised in Figures 2 to 5 below, which 
detail recommended interventions, intervention duration, review periods, maintenance 
and continuation phases (where appropriate) and health professionals involved at each 
stage. Descriptions of each intervention and their evidence-base are provided in 
Appendix 1. Note that interventions listed could be used individually or concurrently. 
For example, for moderate to severe depression or anxiety, cognitive-behaviour 
therapy is often combined with pharmacotherapy for optimal outcomes.  
 
The exact nature of each step, the professionals involved and the interventions 
provided will depend on local resources and current service structure, as well as patient 
preference. Each service should identify its own referral network. Recommendations 
for treatment length are a guide only and will ultimately be determined by clinical 
need, patient situation, and patient preference. 
 
Note that patients may not accept a referral or complete treatment that is offered. The 
ASCO guidelines [17] recommend that health professionals providing psychosocial 
care regularly monitor clinical progress, side-effects and satisfaction with care, the 
frequency depending on the severity of the individual’s condition. If there is limited 
improvement in anxiety and/or depression, low satisfaction, or difficulties with 
adherence to treatment the health professional and patient should review the treatment 
plan making adjustments as necessary. Changes to the treatment plan may include the 
addition of pharmacotherapy, moving from group to individual therapy or moving up 
to the next Step. 
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 It is difficult to say with any certainty how many patients are likely to enter at each 
step since this can vary according to gender, cancer type, stage of disease, time since 
treatment, demographic variables and the measurement instrument used [3-5]. 
However, based on past research it could be expected that most patients will 
experience minimal to mild depression and /or anxiety, with 20-30% experiencing 
moderate to severe depression and/or anxiety [3-5].  
  
 16 
 Figure 2.  
Step 1: Universal care – minimal to mild anxiety/depression.  
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Figure 3 
Step 2: Supportive care – mild to moderate anxiety/depression.  
 
 
Note, health professionals reviewing progress would be expected to have seen the patient before.  
The majority of cancer patients might be expected to enter the stepped care model at Step 2. 
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Figure 4. Step 3: Extended care – moderate anxiety / depression.  
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Figure 5.  
Step 4 and 5: Specialist care – moderate to severe anxiety / depression.  
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Education (face-to-face and online) and brief emotional support from the whole team 
are recommended to respond to minimal to mild anxiety and/or depression (universal 
care) [54,55]. For mild to moderate anxiety or depression telephone help-lines and peer 
support groups or group therapy are recommended in addition [56-61]. Patients 
diagnosed with localized cancer identified as having moderate anxiety or depression 
may benefit from relaxation and stress management training [62-66], problem-solving 
approaches [67] and cognitive behavioural therapy [10-12]. Patients with advanced 
disease may be more likely to benefit from approaches that facilitate the processing of 
existential concerns and fear of mortality, such as mindfulness training, acceptance and 
commitment therapy and supportive-expressive psychotherapy [68-72]. However, 
treatment should always be tailored to the individual, and many patients with localized 
disease also struggle with existential issues and may benefit from therapies addressing 
this also. Internet-based treatments have also been proven effective for people with 
moderate anxiety and depression in the general population, and there is emerging 
evidence for their efficacy in cancer populations also [73,74]. Patients with severe 
disease will need face-to-face interventions, and may require pharmacotherapy. 
 
Pharmacologic Interventions for Mood and Adjustment Disorders 
Depending on the severity of symptoms, pharmacotherapy may be indicated. A 
summary outlining the key principles underpinning pharmacological management of 
anxiety and depression is provided in Appendix 2. For detailed information about 
specific drugs, readers are referred to the Therapeutic Guidelines which are available 
on-line in most public hospitals. The Therapeutic Guidelines: Psychotropic. Version 7, 
2013 [75] provides comprehensive evidence-based information about specific drugs to 
treat anxiety and depression, their side-effect profiles and drug interactions. The 
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Palliative Care Expert Group Therapeutic guidelines: palliative care. Version 3 are also 
helpful [76]. 
 
Suicidal thoughts and self harm 
For patients with moderate or severe anxiety and/or depression a formal risk 
assessment for suicide and self-harm should also be conducted to assess previous 
history, strength of intent, means and capacity. If a patient is found to be at risk of 
suicide or self-harm contact or escort the patient to the emergency department or acute 
mental health team for rapid review and management, and psychiatric intervention as 
appropriate. Discuss with the patient’s treating team. Suicidal thoughts have been 
identified in 6-11% of cancer patients [77-79], although only around 10% of these 
individuals express actual suicidal intent [79]. The presence of other symptoms, such 
as psychosis, severe agitation and confusion (delirium) warrant referral to appropriate 
services for emergency evaluation [19].  
 
Discussion 
The clinical pathway presented above comprises the first attempt internationally to 
develop a comprehensive pathway for managing anxiety and depression in the cancer 
context that provides guidance regarding staffing, timing and potential content of 
interventions, to facilitate implementation into routine practice. We believe the 
pathway provides a further step, beyond guidelines, in assisting oncology services to 
put into place and sustain services that not only identify patients who are suffering 
from anxiety and depression, but also optimise the chances that they receive 
appropriate care.  
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 Of course it is up to individual patients to decide whether or not they wish to accept 
services offered, and many patients access help outside of oncology services or refuse 
help due to stigma, fear, passivity or a desire to help themselves [80]. To increase the 
chances of the pathway producing improved outcomes and to optimise informed 
consent, it is critical to provide education and resources to patients to normalise 
anxiety and depression in the context of a cancer diagnosis and aid their understanding 
of treatment options and their likely benefits and costs. Furthermore, it is important to 
address perceived barriers from the patients’ perspective. Thus in the pathway above, 
we have included online interventions for those with moderate to severe anxiety or 
depression. Web-based interventions, because they allow privacy, some degree of 
anonymity and increased access, overcome many of the barriers known to prevent 
people accessing mental health services. Furthermore, they have been shown in 
numerous trials to be as effective as face-to-face treatment [73,74].  
 
Another advantage of online interventions is that they require minimal staff time, 
freeing psychosocial staff to see the more serious cases which can most benefit from 
expert face-to-face contact. Concern about added time requirements is the primary 
barrier endorsed by clinical staff when considering routine screening for anxiety and 
depression [80]. Hence in addition to addressing patient barriers in implementation 
plans, clinical pathways must be designed to be acceptable to staff and feasible to 
implement.  
 
Another way to minimise demands on staff time, is adoption of electronic patient 
reported outcome (ePRO) systems, increasingly used in cancer clinical care 
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settings[81]. These are superior to paper-based PRO assessments in their potential to 
reduce staff time in overseeing the screening process, accessibility in a range of 
languages, completion in the clinic or remotely, automated scoring of assessments, 
generation of real-time feedback reports to the care team, and linkage into existing 
patient records hence integrating psychosocial information with other clinical 
information. Such systems can be adapted to incorporate clinical pathways such as this 
one, to provide electronic prompts for re-screening, review and discharge summaries, 
as well as links to recommended management and resources. In our own barrier 
analysis for the current pathway [80], participants in structured interviews emphasised 
the importance of being able to track referrals and demonstrate outcomes to ensure 
high quality care and evaluate services. ePRO systems are likely to be utilised in the 
future to enable such processes, and facilitate incorporation of pathways into clinical 
care.   
Another oft-cited barrier to screening and management of anxiety and depression is 
lack of staff training and education. Education is needed to target screening, assessing, 
making a referral - particularly when patients are reluctant - and empathic 
communication. It is also critical that cancer services staff understand each other’s 
roles and responsibilities in order to integrate processes for screening, referral and 
providing after-care for patients [81]. Such training and support is already available 
online, through the Canadian Association of Psycho-Oncology IPODE website 
at http://www.capo.ca/ipode-project/screening-for-distress, and is delivered face-to-
face in many other sites. Materials such as these, adapted for the local context, will 
facilitate uptake of the pathway.  
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It is important that pathways like this one are empirically tested to ensure they are 
feasible and acceptable to health services, are actually implemented, and lead to 
improved patient care. We are currently undertaking such an evaluation in Australia.  
 
Limitations 
This pathway was developed in the Australian context, and may not be applicable to all 
health systems, particularly those of low income countries where some resources may 
be unavailable. Even in developed countries these resources are all too frequently not 
integrated or available.  
 
Furthermore, this pathway is general, and does not detail how to respond to issues that 
may be specific to particular disease sites, disease stages, cultures, sexes, ages, etc. Nor 
does it address the needs of the family who may have distress as great as, or greater 
than, the patient themselves. 
 
We were not able to find enough evidence to guide us, or to gain consensus from our 
Delphi panel, regarding the optimal timing for re-screening and assessment. Panel 
members felt this was a very individual decision, based on client needs. Further clarity 
on this issue would be beneficial to explore both in research and in future guidelines.  
 
New evidence is always emerging, and the pathway will need to be periodically 
updated. However, the structure and content of the pathway were developed to allow 
this to occur easily. We suggest updating at 5 yearly intervals to incorporate new and 
emerging data.  
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In summary, we hope the pathway for anxiety and depression in the cancer context 
will facilitate fully integrated and effective screening, detection and management of 
anxiety and depression in cancer services, and aid in reducing the enormous burden of 
suffering that patients with these psychological morbidities experience, as well as 
reducing the economic costs to services that are incurred when anxiety and depression 
are not adequately treated. While clearly delineated pathways such as these facilitate 
implementation, careful attention to patient, health professional and system barriers 
will optimise chances of success. 
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Table 1. Professional roles.# 
 General 
practitioner 
Treating 
clinician* 
Nurse** Social 
worker 
Clinical 
Psychologist 
Psychiatrist 
Screening    X X X X   
Clinical assessments       X     X      X     X X X 
Formal diagnosis              X X 
Self harm risk 
assessment X X   X X 
Supportive care for 
physical symptoms 
(e.g., pain, fatigue) 
X X X    
Psycho-education X X X X X X 
Supportive 
counselling X X X X X X 
Referral to psycho-
oncology service X X X X   
Relaxation strategies X  X X X X 
Support group 
facilitation   X X X  
Skills training e.g., 
problem-solving    X X X 
Psychological 
therapy     X X X 
Psychosocial training 
for other health profs      X X 
Referral to 
psychiatrist X X   X  
Pharma-cotherapy X X    X 
Follow up  X X X X X X 
#   Developed by the multidisciplinary panel, and confirmed by the Delphi process 
*   Surgeon, medical oncologist, radiation oncologist, haematologist, palliative care physician 
** Cancer care coordinator, nurse specialist, clinical nurse specialist, clinical nurse consultant, general  
     cancer nurses, palliative care nurse  
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Table 2. Signs and symptoms of anxiety and depression* 
 
Anxiety Depression 
• Autonomic arousal (e.g. accelerated heart 
rate, sweating, trembling, dry mouth) 
• Symptoms of chest and abdomen (difficulty 
breathing, feeling of choking, chest pain, 
nausea) 
• Symptoms of brain and mind (feeling dizzy, 
unsteady, faint or light-headed, feeling 
objects are unreal, depersonalization, fear of 
losing control or dying, difficulty 
concentrating, mind going blank, irritability) 
• General symptoms (hot flushes or cold chills, 
numbness or tingling) 
• Symptoms of tension (muscle tension or 
aches and pains, restlessness, inability to 
relax, difficulty swallowing, lump in throat) 
• Difficulty getting to sleep because of 
worrying. 
• Lowered mood 
• Decreased energy and activity 
• Marked tiredness after activity 
• Diminished pleasure, interest and 
concentration 
• Loss of libido 
• Significant change in appetite and sleep 
patterns (loss of appetite, early wakening) 
• Reduced self esteem and self confidence 
• Feelings of worthlessness or excessive, 
inappropriate guilt 
• Recurrent thoughts of death or suicide 
 
* Based on ICD-10 [47] 
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Table 3. Characteristics of mild, moderate and severe anxiety and depression.# 
  
 Anxiety Depression 
Mild • Has two or three of the above symptoms, 
proportion to stressors, e.g. worry, 
uncertainty about future, concerns re illness  
• Person is distressed but can continue with 
activities 
• Has two or three of 
above symptoms.  
• Person is distressed but 
can continue with most 
activities 
  
Moderate • Four or more of above symptoms 
• Cancer-related worries shift from one topic 
to another, including both major and minor 
concerns and difficult to control  
• Person is very distressed and having great 
difficulty continuing usual activities 
•  
• Four or more of above 
symptoms 
• Person is distressed and 
having great difficulty 
continuing normal 
activities 
•  
Severe  
 
• Four or more of above symptoms consistent 
with a diagnosed anxiety disorder (eg 
phobia, generalised anxiety disorder (GAD), 
panic, post-traumatic stress disorder (PTSD), 
obsessive compulsive disorder (OCD)  
• Symptoms are severe and distressing and the 
person is unable to continue usual activities 
and may be housebound  
• Co-morbidity may be present 
• Four or more of above 
symptoms consistent 
with a diagnosed 
depression 
• Symptoms are severe and 
distressing and the 
person is unable to 
continue usual activities 
• Loss of self esteem, 
worthlessness and guilt  
• Suicide ideation  
• May have some 
psychotic elements 
(hallucinations, 
delusions, psychomotor 
retardation)  
# Based on ICD-10 [47] 
 Note, symptoms of anxiety in cancer patients are difficult classify because they can be a normative or excessive reaction to cancer threats, a response to poor symptom control, an adverse effect of certain treatments or drug interactions, a clinical anxiety disorder, or a combination of these factors.  
Risk factors for anxiety and depression in cancer patients include [32]  
o Recurrent, advanced, progressive disease (ie disease-induced  vulnerability) or presence of 
chronic illnesses in addition to cancer 
o History of depression, substance use of abuse, other mental health problems 
o Perceived lack of social support 
o Other factors (e.g. younger age, female, living alone, dependent children, financial problems) 
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Table 4. Assessment for suicide risk.* 
 
 Risk Factors Scoping questions 
 
Suicidal Ideation 
Suicidal Plan 
Access to means 
Prior Attempts 
High levels of Anger / Hostility / Impulsivity 
Current Depression  
Current Anxiety:  
Disorientation / Disorganisation  
Hopelessness 
Identifiable Stressors 
Substance Abuse 
Psychosis 
Poor Medical Status 
Withdrawal from Others 
Expressed Communication 
Psychiatric Service History 
Poor Coping Strategies 
Lack of Supportive Others (connectedness)  
High Carer/Family/Significant Other Perception of Risk 
History of Violence/Aggression/Self-Harm 
Family History of Mental Illness or Suicide 
 
  
 
 Have things been so bad lately that 
you have thought you would rather 
not be here? 
 Have you had any thoughts of 
harming yourself? 
 Are you thinking of suicide? 
 Have you ever tried to harm 
yourself? 
 Have you made any current plans? 
 Do you have access to a firearm or 
other ways of harming yourself? 
 
• Based on the Australian Psychological Society Suicide Risk Assessment Tool 
https://www.psychology.org.au/Assets/Files/Risk%20assessment%20guide.pdf 
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APPENDIX 1: Description and evidence-base for interventions for anxiety and 
depression  
Patient education/Psycho-education: the formal or informal provision of 
information, delivered through informal discussion, brochures, formal educational 
sessions, and video, audio and online resources, to improve knowledge and reduce 
uncertainty and improve physical side-effects such as pain [54].  
Brief emotional support: health care professionals confidently and comfortably 
discussing anxiety and depression with patients. Can help to prevent the emergence of 
anxiety and depression and/or identify it early [55].  
Tele-based cancer help-lines: offer emotional support for people with cancer in 
addition to providing psycho-educational materials and referral to further psychosocial 
services, if needed over the phone [56-58]. Particularly helpful for geographically-
isolated patients. Have been shown to reduce levels of anxiety and depression[56-58]. 
Internet-based interventions: provide psychological therapies online. As effective as 
face-to-face care for mild to moderate anxiety and depression [73,74]. 
Peer support groups/group therapy: facilitate mutual support between people and 
provide opportunities to learn coping skills in a non-judgmental and caring 
environment. Effective in reducing anxiety and depression [59-61].  
Problem solving approaches: focus on generating, applying and evaluating solutions 
to identified problems [67]. Effective in reducing anxiety and depression [67]. 
Relaxation skills: techniques designed to induce physical and mental relaxation, 
including progressive muscle relaxation, guided imagery and hypnosis. Effective in 
reducing anxiety and depression [65-66]. 
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Stress management: provide training in anxiety-reduction skills, increased awareness 
of sources of stress and indicators of stress, noticing and replacing negative thoughts to 
improve the ways patients manage stressors[62]. Stress management has been shown 
to improve emotional well-being and positive affect [62-64].  
Mindfulness: teach patients to increase awareness of thoughts and the impact they can 
have on symptoms of anxiety and depression, with the aim of interrupting these 
automatic processes and facilitating non-judgmental awareness of thoughts.[68] 
Include mindfulness-based stress reduction (MBSR), mindfulness-based cognitive 
therapy (MBCT), and Acceptance Commitment Therapy (ACT). Effectively reduce 
anxiety and depression [68, 71]. 
Cognitive behavioural therapy (CBT): focuses on identifying, challenging, and 
changing maladaptive thoughts and behaviours to reduce negative emotions and 
promote psychologic adjustment [10]. One of the most common therapies used, with 
proven effectiveness in for anxiety and depression [10-12]. 
Supportive-expressive therapy/Supportive psychotherapy: “focuses on the 
communication and processing of subjective experience and on the joint creation of 
meaning within a therapeutic relationship to reduce distress” [69]. Targeted and 
manualised psychotherapies, particularly for those with advanced illness, have recently 
been developed, including Meaning-Centred Group Therapy, Dignity Therapy, 
Mindfulness-Based Meditation Therapy, and a brief supportive-expressive intervention 
referred to as CALM (Managing Cancer and Living Meaningfully[72]). Supportive-
expressive therapy is effective against depression and cancer-related distress [69,70]. 
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APPENDIX 2: PHARMACOLOGIC INTERVENTIONS FOR MOOD AND 
ADJUSTMENT DISORDERS 
Depending on the severity of symptoms, pharmacotherapy may be indicated. The aim 
of this section of the document is to outline the key principles underpinning 
pharmacological management of anxiety and depression. For detailed information 
about specific drugs, readers are referred to the Therapeutic Guidelines which are 
available on-line in most public hospitals. These Guidelines are developed by an expert 
group and are regularly updated. The general information below is based on 
information in Therapeutic Guidelines referenced below unless stated otherwise.  
DEPRESSION 
There is strong evidence that anti-depressants effectively treat clinical depression [82]. 
No particular class of antidepressants has been shown to be more effective than 
another in the treatment of depression [68], with direct comparison between classical 
tricyclic antidepressants and SSRIs in a number of head-to-head trials showing no 
differences [83].  
Compared with the general adult population, prescription of antidepressant medication 
for patients with cancer is more complex, and a number of factors must be taken into 
account in both selection of a particular drug and the dose, including: 
• Side-effect profile – for example, there is potential for initial exacerbation of 
nausea and sleep disturbance, and some drugs can lower seizure threshold;  
• Potential for drug interactions – for example, SSRIs may interact with 
anticonvulsants, anticoagulant therapy, and tamoxifen. Some SSRIs have a long 
half-life with active metabolites meaning that the potential for ongoing 
interactions increases. Some drugs when prescribed with SSRIs will increase 
the risk of serious adverse serotonin-related toxicity; 
• Patient response to previous treatments; 
• Family history of response to treatments; 
• Patient comorbidities – for example elderly patients are vulnerable to 
exacerbation of pre-existing cognitive deficits and the development of 
confusion, and in patients with pre-existing heart disease, renal impairment or 
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liver disease the choice of drug is affected, and dose reduction will commonly 
be required; 
• The potential for beneficial impact on other symptoms – for example 
improvement in sleep, treatment of hot flushes, or as an adjunct to treatments 
for pain.  
In the general adult population the first-line pharmacological treatment of depression 
will most commonly be an SSRI or SNRI, mainly because of their more favourable 
side-effect profile compared with the older drugs such as TCAs.  
In patients with cancer, TCAs may have a valuable role even in low dose to relieve 
sleep disturbance and assist with pain management. However their side-effect profile 
(especially anticholinergic effects) may limit treatment and their use can be associated 
with troubling side-effects including constipation, urinary retention and postural 
hypotension. Note that TCAs are lethal in overdose and should not be prescribed for 
patients for whom suicide is considered a risk.  
Stimulants such as methylphenidate and dexamethasone have been used in a palliative 
setting because of their rapid onset of action and their effect on other symptoms such 
as attention and concentration. However there is a lack of evidence and recent 
European Guidelines on the management of depression in a palliative setting do not 
recommend the use of psychostimulants [82]. The Therapeutic Guidelines Version 7, 
2013 provides comprehensive evidence-based information about specific drugs to treat 
depression and anxiety, their side-effect profiles and drug interactions.  
 
RESISTANT DEPRESSION 
It may take two to four weeks before an improvement in mood is evident after 
initiation of antidepressant treatment. It is important to remember that when using 
antidepressant medication, the patient continues to require frequent and regular contact 
with and psychological support from their treating clinician to promote full recovery. 
Failure to respond to treatment should lead to a systematic approach comprising: 
• Review of the diagnosis – for example is this really depression rather than 
grief? Delirium should always be considered as a possible underlying condition 
in a medically – ill person with sudden onset of mood disturbance;  
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• Exclusion of any other contributory condition (for example identification of 
unaddressed alcohol abuse or other causes of a depressive syndrome such as 
hypothyroidism, metabolic disturbance such as hypercalcaemia or central 
nervous system disease);  
• Review of any problems with adherence to medication; 
• Review of psychosocial and personality factors, and adequacy of concurrent 
psychological support/intervention; 
• Review of drug interactions (including depressive syndromes secondary to 
other medications such as corticosteroids, antihypertensive agents); 
• Finally review and titration of the dose. The Therapeutic Guidelines lists dose 
ranges for antidepressants.  
If the person’s mood fails to improve with the above steps specialist review is 
recommended. Augmentation with other medication may be appropriate, and in some 
instances ECT may be considered as the safest and most effective treatment option.  
ANXIETY 
Psychological interventions which might include a combination of CBT, relaxation 
training and guided imagery are the first-line therapy for generalized anxiety. 
Pharmacotherapy will be indicated if psychological interventions do not provide 
sufficient improvement in symptoms, or when relief of anxiety is required urgently, for 
example in order for a patient to complete a course of radiotherapy. 
SSRIs are the first line choice of medication for treatment of anxiety requiring 
pharmacotherapy [51]. Patients who are anxious may be highly sensitive to the side-
effects of medication, which can include an initial exacerbation of anxiety and sleep 
disturbance. For this reason, some clinicians may choose to commence drug treatment 
with a lower dose than usual and increase the dose as the person adjusts to side-effects. 
Benzodiazepines have a limited role in the treatment of anxiety disorders and are not 
first-line treatment except in a short-term crisis situation (for example, a patient who 
requires fitting of a face-mask for radiotherapy or in palliative care settings). Use of 
benzodiazepines is associated with significant morbidities including confusion, ataxia 
and falls in the elderly. Development of dependence and tolerance can occur within 
one month of regular consumption. Use of benzodiazepines with a short half-life can 
 41 
lead to rebound anxiety and a cycle of dosage escalation as the person interprets their 
symptoms as requiring more medication. 
Antipsychotic medication for the treatment of anxiety is not recommended. Older 
persons are especially vulnerable to the side-effects of antipsychotic medication and 
there are reports of increased risk of cardiac events and stroke associated with their use 
in this population. The following guidelines provide useful overviews. 
Psychotropic Expert Groups. Therapeutic guidelines: psychotropic. Version 7. 
Melbourne: therapeutic Guidelines Limited; 2013. ISBN 978-9808253-9-8 
Palliative Care Expert Group. Therapeutic guidelines: palliative care. Version 3. 
Melbourne: Therapeutic Guidelines Limited; 2010. ISBN: 97809804764 
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